Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
BEIJING, Nov. 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it was selected by the Shanghai Government to supply its inactivated hepatitis A vaccine, Healive, to the public market of Shanghai. Out of the five vacc...
Sinovac Reports Unaudited Third Quarter 2009 Financial Results
- Conference call scheduled Monday, November 16, 2009 at 9:00 a.m. ET - BEIJING, Nov. 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today its unaudited financial results for the three-month and nine-month periods ended S...
Sinovac to Host Conference Call to Report 2009 Third Quarter Financial Results
BEIJING, Nov. 10 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Monday, November 16, 2009 at 9:00 a.m. ET to review the Company's third quarter financial results for the period ended Sept...
Sinovac to Transfer Stock Exchange Listing to NASDAQ Global Market
BEIJING, Nov. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it will voluntarily transfer its stock exchange listing from the NYSE Amex to the NASDAQ Global Market. It is anticipated that Sinovac...
Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
Enters Shanghai Market with Purchase Order for Seasonal Influenza Vaccine Anflu(R) BEIJING, Oct. 27 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its third purchase order for its H1N1 va...
Sinovac Receives Certificate of Approval to Distribute PANFLU.1 (H1N1) in Mexico
First China-Developed Vaccine Approved for Human Use in Mexico BEIJING, Oct. 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has received a Certificate of Approval from the Secretaria de Salud to...
Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
BEIJING, Oct. 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) Ltd, has received the Certificate of Approval to distribute Panflu(TM) (H5N1), its...
Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
BEIJING, Sept. 30 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac has received its second purchase order for its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and Information Technology of ...
Sinovac Biotech Ltd. Files Annual Report on Form 20-F
BEIJING, May 2 /PRNewswire-Asia-FirstCall/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 200...
Sinovac to Present at 2009 UBS Global Life Sciences Conference
BEIJING, Sept. 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Weidong Yin, Chairman, President & CEO, will present at the 2009 UBS Global Life Sciences Conference in New York City. The presentati...
Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
BEIJING, Sept. 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that the first lot of PANFLU.1, its H1N1 vaccine, has passed the lot release process of China's National Institute for the Control of Pharmaceutical and Biolo...
Sinovac Obtains Production License for H1N1 Vaccine
BEIJING, Sept. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the State Food and Drug Administration (SFDA) has approved the registration application for PANFLU.1, Sinovac's H1N1 vaccine, and has issued Sin...
Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
Clarifies Details of Agreement with Boryung BEIJING, Sept. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that it has signed an agreement with Boryung Pharmaceutical Company Limited, a Korean manufacture...
Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac's H1N1 vaccine has passed the experts evaluation organized by State Food and Drug Administration (SFDA). The vaccine is expect...
Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
BEIJING, Aug. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public Health Bureau has selected Sinovac as one of the four manufacturers to supply Anflu(R), Sinovac's seasonal influenza vaccine,...
Sinovac Reports Unaudited Second Quarter 2009 Financial Results
- Conference call scheduled Wednesday, August 19, 2009 at 8:00 a.m. ET - - Reaffirmation of 2009 sales projection to be $55 million to $60 million - - H1N1 vaccine may drive additional growth - BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE A...
Sinovac Reports Top-Line Preliminary Results of H1N1 Vaccine Clinical Trials
- Results Show Good Safety Profile and Immunogenicity - BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine...
Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended ...
Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
-H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers received their first ...
Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
BEIJING, July 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, today announced that it has initiated dosing today in its clinical trial of various Panflu vaccine candidates for pandemic influenza A (H1N1). Results are expected in September 2...
